New clinical study to broaden the use of TUBEX® TF on the African market
AroCell announces today that a new evaluation study of the TUBEX® TF product starts in Uganda. This study will be conducted in collaboration with the Uganda National Public Health Laboratory Services (UNHLS). The study is carried out for documentation of TUBEX® TF and will after a positive outcome work as a basis for market approval and sales.
“AroCell is actively working to establish TUBEX in several African markets. Given positive study results, our distributor Medilink Lab and Surgicals Limited can start sales in Uganda. The study is estimated to be completed within 6-12 months", says Anders Hultman, AroCells CEO.
TUBEX® TF is a bacteriological rapid test for a simple and safe diagnosis of typhoid fever, the most serious form of salmonella. Typhoid fever is a water- and food-borne infectious disease that can be fatal if the correct diagnosis is not made and treatment is initiated. According to the WHO, 11–20 million new cases are diagnosed annually, of which more than 160,000 lead to deaths, mainly among children.
Typhoid fever causes high fever, flu-like symptoms, and severe diarrhea, and is potentially life-threatening if not treated properly. Due to the symptoms, the patient may be misdiagnosed with diseases such as malaria, dengue fever, or pneumonia. As typhoid fever is treated with antibiotics and antibiotic resistance is, unfortunately, a growing problem, rapid testing, and correct diagnosis is a further argument for the need.